Anti-VEGF Prior Authorization Services
Outsource your anti-VEGF prior authorization queue to remote retina-trained BPO specialists. Built for retina practices and general ophthalmology groups that run injection clinics. Same-day submission, structured follow-up at 24 and 48 hours, peer-to-peer ready. Submitted by retina-trained PA specialists, not generalists.
Anti-VEGF Prior Authorization, handled by a dedicated remote team
Trained specialists handle it inside your existing software, so your team stays on patient care.
With Staffingly, anti-vegf prior authorization outsourcing means a dedicated team of trained specialists running this part of your back office. They are named to your account and work remotely as an extension of your staff, not a shared offshore pool. As a HIPAA-compliant healthcare BPO, we bill a flat weekly fee per specialist, never a percentage of your collections.
Anti-VEGF prior auth, done by retina-trained specialists
Wet AMD, diabetic macular edema, and retinal vein occlusion patients lose vision when injections are delayed. We treat the anti-VEGF prior authorization queue as a clinical priority, not a paperwork pile. Same-day submission for cases received before 2pm Eastern. Structured follow-up at 24 and 48 hours. Peer-to-peer scheduling and documentation packaging when payers ask for it.
Each anti-VEGF case lands in our queue with a clinical packet attached: OCT progression maps, fluorescein or ICG angiography where relevant, BCVA trend, central subfield thickness numbers, and prior treatment history. Our team is trained to read those clinical assets before submitting, not after. That is how we avoid the round-trip that pushes a wet AMD patient out another two weeks.
We follow the American Academy of Ophthalmology guidance on retina prior authorization and use payer-specific clinical criteria for Aetna, BCBS, UHC, Humana, Cigna, Medicare Advantage, and state Medicaid managed care plans. Step therapy mandates, biosimilar substitutions, and bevacizumab-first language are all handled at intake, not at denial.
This spoke runs alongside our main Eye Care services hub . For surgical PA see the IOL and cataract surgery prior auth spoke .
Tell us about your practice.
Send us your situation and our team will scope the right setup, usually within one business day. No obligation.
Drugs and admin codes we submit every day
Verified against CMS, AAPC, and the American Academy of Ophthalmology 2026 coding guidance.
Codes verified against CMS Medicare Coverage Database article A52451 (ranibizumab/aflibercept/faricimab) and current AAO injectable drug coding guidance. Payer-specific coverage policies still apply.
| HCPCS / CPT | Drug or Service | Billing Unit | Notes |
|---|---|---|---|
| J0178 | Aflibercept (Eylea) | 1 mg, billed as 2 units per eye | Most-used wet AMD agent |
| J0177 | Aflibercept HD (Eylea HD) | Permanent J-code, 8 units | Higher-dose extended-interval option |
| J2778 | Ranibizumab (Lucentis) | 0.1 mg per unit | Biosimilars available; payer-specific |
| J2777 | Faricimab (Vabysmo) | Billed as 60 units | Dual VEGF / Ang-2 inhibition |
| J7999 | Bevacizumab (Avastin), compounded | Compounded drug, NOC | Off-label ophthalmic use; payer policies vary |
| Q5160 | Bevacizumab-nwgd (jobevne) | 10 mg, effective 01/01/2026 | New biosimilar code per CMS |
| 67028 | Intravitreal injection (admin) | Per injection, per eye | Modifier 50, RT, or LT as appropriate |
Three reasons our anti-VEGF queue moves faster
Clinical packet at submission
OCT central subfield thickness, BCVA, prior treatment, intolerance notes, and indication ICD-10 are packaged at submission. Payers do not get a chance to ask for more before responding.
24 and 48 hour follow-up
Every submission has a follow-up scheduled at 24 and 48 hours. No PA sits silent. We chase the payer, not the patient.
Peer-to-peer ready
When a payer asks for P2P, we schedule it, brief your physician, and stage the OCT and FA images so the call takes five minutes, not thirty.
How we run an anti-VEGF PA end to end
Every step has a named owner, a target SLA, and a documentation handoff.
Intake by 2pm Eastern
Cases received before 2pm Eastern hit the same-day submission queue. After 2pm we batch for next-day morning submission.
Clinical packet build
OCT progression, BCVA trend, ICD-10 confirmation, prior step therapy, intolerance notes. Payer policy quoted in the submission.
Portal submission
Availity, NaviNet, Cigna provider portal, UHC Link, or fax where the payer requires it. Submission ID logged in the EMR.
24-hour status check
If still pending, we check portal. If a clinical question is open, we route to the doctor for a 60-second clarification.
Peer-to-peer when needed
Slot booked. Doctor briefed. OCT and FA images pulled. P2P call takes 5 minutes, not 30. We document the outcome in the EMR.
Approval routed to scheduling
Approval logged in the EMR, injection chair slot confirmed, patient called within the same business day with the appointment.
AI + Retina-Trained Clinicians = Faster PA Approvals
Staffingly AI and workflow automation handle the repetitive parts of eye care prior authorization. Form auto-fill, payer rule matching, step-therapy lookups, peer-to-peer scheduling. Every case still reviewed by retina-trained specialists before submission.
AI Clinical Sandbox
Validates anti-VEGF (J0178, J0177, J2778, J2777) and cataract (CPT 66984) PAs against payer rules before submission. Catches missing OCT, BCVA, step therapy.
Same-Day Submission
AI form-fill automation pulls patient data from your EMR. Submission goes out the same day you order, not the same week.
Denial Pattern Analytics
Automation tracks denial reasons by payer, drug, and CPT in real time. Practice gets a monthly denial-pattern report to fix upstream documentation.
Peer-to-Peer Auto-Routing
Automation flags every denial that qualifies for P2P. Coordinator packages OCT progression, FA, BCVA, step therapy. Physician walks into a prepped call.
- HIPAA Compliant
- SOC 2 Type II
- ISO 27001
- End-to-End Encryption
- BAA Before Pilot
How Staffingly works, in practice
Inside the work A trained Staffingly specialist handles the workflow inside your existing practice software, with clear escalation back to your team.
One Flat Weekly Rate. No Surprises.
Dedicated specialists at a fixed weekly cost. Per specialist FTE, per week. No contracts, no minimums, no hidden fees.
Want to compare against an in-house hire? Use the savings calculator.
Frequently asked questions
Which anti-VEGF drugs do you submit prior authorizations for?
We submit anti-VEGF prior authorizations for Eylea (aflibercept, J0178), Eylea HD (J0177), Lucentis (ranibizumab, J2778), Vabysmo (faricimab, J2777), Avastin (bevacizumab, J7999 compounded for ophthalmic use), and the new bevacizumab-nwgd jobevne (Q5160, effective January 1, 2026). We also handle biosimilar substitutions when payers mandate them.
What is the typical turnaround for an anti-VEGF prior authorization?
The American Academy of Ophthalmology reports an average of two to seven days once documentation is complete. Our team submits same-day for cases received before 2pm Eastern, follows up at 24 and 48 hours, and books peer-to-peer slots when payers ask. Most approvals return within 48 to 72 hours when clinical documentation is clean at submission.
Do you handle peer-to-peer for anti-VEGF denials?
Yes. We schedule the peer-to-peer call, package the clinical documentation including OCT progression, fluorescein angiography, prior step therapy notes, and visual acuity trends, and brief your physician before the call. Many practices route the P2P call directly to our retina-trained coordinators who handle level-one peer-to-peer scripts and only escalate to the doctor for clinical judgment moments.
How do you handle bevacizumab-first step therapy mandates?
We document Avastin trial history, intolerance, or contraindication at the front of the submission when payers require it. We also handle the new bevacizumab-nwgd jobevne (Q5160) workflow that started January 1, 2026. When a payer requires repackaged bevacizumab over compounded Avastin, we route to the practice's preferred 503B compounding pharmacy and document the supply chain in the PA submission.
Should I outsource anti-VEGF prior authorization for my retina practice?
For most retina practices the answer is yes. The American Academy of Ophthalmology reports 53% of ophthalmologists already have staff working exclusively on prior authorization, and that salary line is a direct margin hit. A remote PA specialist trained on Eylea (J0178), Eylea HD (J0177), Lucentis (J2778), Vabysmo (J2777), and Avastin (J7999) costs less than the in-house equivalent and turns same-day submission with structured 24/48 hour follow-up into a default. The result is the injection clinic stops losing chair time to denials.
How much does anti-VEGF prior authorization outsourcing cost?
Staffingly anti-VEGF PA outsourcing is a flat $399 per specialist per week for a single-position engagement, $349 per specialist per week at 5+ specialists, and $299 per specialist per week at 10+ resources. Each PA specialist works 45 hours per week, fully managed. No long-term contract. The 2-Week Free Pilot is included so you see real anti-VEGF submissions on your real queue before any invoice.
President and CEO, Staffingly, Inc. 25+ years in IT consulting and healthcare BPO operations. One of the earliest US operators to set up an RPO/BPO delivery network in India. Leads AI-driven optometry and ophthalmology workflows that help vision practices and multi-location groups cut admin cost without compromising care.
